Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
BACKGROUND
The major beneficial effect of statins- reducing the risk for coronary events-has primarily been ascribed to reductions in low-density lipoprotein cholesterol (LDL-C) but may in part be related to a direct antiinflammatory action (ie, decreased high-sensitivity C-reactive protein [hs-CRP] concentration).
OBJECTIVES
The objectives of this CAP… (More)
Low-density Ilpoprotelndependent and -Independent e~ fects of cholesterol-Iowenng therapies on C-reactive protein: A metaanalysIs
S. Klnlay
Am Call Cardlol
2009
C-reactive protein (CRP) gene polymorph Isms, CRP levels, and nsk of incident coronary heart disease In two nested case-control studies
JK Pal, KJ Mukamal, KM Rexrode, EB. Rlmm
PLoS ONE
2008
Companson of effects of high (80 mg) versus low (20 mg) dose of slmvastatln on C-reactive protein and lipoproteins In patients with anglographlc eVidence of coronaryartenal narrowing
KG Meredith, BD Horne, RR Pearson
AmJ Cardlol
2007
A tale of two tnals: A companson of the post-acute coronary syndrome llpld-lowenng tnals A to Z and PROVE IT-TIMI 22. Circulatlon.2006;113:1406-1414
SD WIVIOtt, JA de Lemos, CP Cannon
2006
C-reactive protein contnbutes to the hypercoagulable state In coronary artery disease
CJ Song, A Nakagoml, S Chandar
J Thromb Haemost
2006
C-reactive protein promotes platelet adhesion to endothelial cells: A potential pathway
G Yaron, A Bnll, 0 Dashevsky
In atherothrombosls. BrJ Haematol
2006
Clinical relevance of Creactive protein dunng follow-up of patients with acute coronary syndromes In the Aggrastat-to-Zocor Tnal
DA Morrow, JA de Lemos, MS Sabatine
2006
Cytokl nes In atherosclerosIs: Pathogenic and regulatory pathways
A Tedgu I, Z. Mallat
Physiol Rev
2006
Is C-reactive protein an Innocent bystander or proatherogenlc culpnt? The verdict IS still out. Circulation